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Abstract
Neuroblastoma is the commonest extracranial solid tumor in children, and metastasis at
presentation is seen in more than 50% of cases. The role of radiotherapy as a palliative
modality in patients with advanced neuroblastoma provides better symptomatic relief.
Palliative radiotherapy dose schedules can be given either in single hypofractionation
from 4 to 8 Gy or fractionated radiotherapy that can range from 21 to 30.6 Gy. Doseresponse relationship trend has been reported in the palliative setting of bone metastasis. Because of the proximity of tumor to critical organs, serious adverse effects can be
avoided with conformal techniques. Although currently there is limited data available,
new treatments with particle therapies are undergoing clinical evaluation and may offer
new hope for good quality of life in these patients.
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1. Introduction
Rudolf Virchow, a German physician, was the first person who described neuroblastoma
in 1864. Through his research he called the tumors found in the abdomens of children as
gliomas. In 1910, James Homer Wright made great efforts to map the origin and development
of tumor cells, and he named the tumors neuroblasts, as “blastoma” refers to a collection of
immature, undifferentiated cells [1]. His meticulous study showed that these tumors originated from an immature, primitive form of neural cell. The term neuro denotes to “nerves,”
while blastoma denotes to a “cancer that affects immature or developing cells.” Neuroblasts
which are formed during embryonic stages develop normally once fetus matures after birth.
Sometimes due to uncontrolled cell divisions, they become cancerous, causing neuroblastoma (Figure 1).
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Figure 1. Primordial neural crest cells which develop into the adrenal medulla and sympathetic ganglia during
specification and differentiation that lead to formation of neuroblastoma. Adrenal gland is the most common site of
origin, but sympathetic nervous system chain from the neck to the pelvis can be other common site of origin.

2. Epidemiology
This set of tumors is considered almost exclusively a disease of pediatric population. Neuroblastoma is the most common solid extracranial tumor, accounting for third most common childhood cancer, after leukemia and brain tumors. Neuroblastoma accounts for approximately 15%
of all pediatric cancer fatalities with almost 600 new cases are diagnosed in the United States each
year. White race infants displayed more incidence of neuroblastoma than black infants (ratio of
1.7:1 for male and 1.9:1 for females), but little of any racial difference is apparent among older
children. Males have higher incidence rate relative to females (male-to-female ratio of 1.3:1) [2].
Neuroblastoma is thought to occur sporadically, with 1–2% of cases are familial [3].

3. Clinical presentation
Patients with neuroblastoma present with a combination of signs and symptoms which are
nonspecific and are variable. They depend on site of tumor, size, degree of metastatic spread,
and catecholamine secretion.
3.1. Primary disease
Neuroblastomas in the abdomen are the most common form that arises in 65% of cases,
approximately 50% arises from the adrenal glands (adrenal neuroblastoma), and one-third
are from paravertebral ganglion (extra-adrenal neuroblastoma). Abdominal mass which is
asymptomatic may be an incidental finding which is usually detected by parents [4].
Symptoms are abdominal pain or fullness and abdominal mass which is usually firm and fixed.
Characteristic nodularity of abdominal neuroblastomas is similar to palpating a bag of potatoes
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which differentiates it from a nephroblastoma. In some cases, enlarged liver, spleen, and
intestinal obstruction may be seen. Rarely, scrotal and lower extremity edema results from
the compression of venous and lymphatic drainage of the lower extremities due to size of
primary or metastatic abdominal tumors. Renin-mediated hypertension is because of compromised renal vasculature. Epinephrine is rarely released from most neuroblastomas due
to deficiency of enzyme necessary for synthesis. So hypertension, tachycardia, flushing, and
sweating are uncommon symptoms. Hypertension and opsomyoclonus detected in less than
2% are part of paraneoplastic syndromes [5].
3.2. Metastatic disease
More than 50% of patients present with metastatic disease. Neuroblastoma is associated with
lymphatic and hematogenous spread. Common hematogenous metastatic sites are the bone
marrow (70.5%), bones (skull, long bones, ribs, vertebrae, 55.7%), liver (29.6%), and skin and
rarely the brain or lungs. Thirty-five percent of patients had regional lymph node metastases
with localized tumors [6].
3.2.1. Signs and symptoms of metastasis
Long bone involvement causes pain and limping with increasing risk of pathological fractures which is known as Hutchinson syndrome. Periorbital ecchymoses, swelling, and
proptosis (raccoon eyes) occur due to sphenoid bone and retrobulbar tissue involvement.
Painless proptosis, periorbital edema, and ecchymosis of the upper lid are akin with trauma
or child abuse. Irritable and fussy infant needs attention. Bone marrow involvement may
result in pancytopenia. Huge involvement of the liver in metastatic condition is common in
infants with stage Ms/4S and may cause Pepper syndrome (PS), which induces the respiratory
distress, quoted by W. Pepper [7]. PS was recognized as a localized primary tumor and metastatic condition restricted to the skin, bone marrow, and liver in infants. PS is usually known
for better prognosis, as it is linked with spontaneous regression of disease. Some infants with
stage 4S neuroblastoma die of massive hepatomegaly, respiratory failure, and overwhelming sepsis. Non-tender, bluish, and mobile skin and subcutaneous nodules are because of
metastasis to these sites. This is known as “blueberry muffin sign.” These nodules become

Figure 2. Spinal cord compression by vertebral body metastasis and extension of tumor posteriorly into the epidural space.
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prominently red once provoked and thereafter blanch for some minutes, due to release of
vasoconstrictive metabolic products. These nodules can be diagnostic of neuroblastoma and
should be differentiated from metastatic skin leukemic infiltrates.
Paraspinal tumors in the thoracic, abdominal, and pelvic regions often present with spinal
cord compression due to spinal canal invasion through the neural foramina causing symptoms related to compression of nerve roots and spinal cord. There may be subacute or acute
paraplegia, bladder or bowel dysfunction, or less commonly radicular pain. Cervical neuroblastoma may present as Horner’s syndrome [8] (Figure 2).

4. Prognosis according to MYCN amplification status
In infants, MYCN (neuroblastoma-derived, v-myc avian myelocytomatosis viral related
oncogene) amplification and unfavorable Shimada histopathology correlated with increased
frequencies of bone and intracranial or orbital metastases. In geriatric patients, MYCN amplification is associated with increased risk of intracranial or orbital and lung and liver metastases [6]. MYCN amplification status defines response rate to palliative radiotherapy. Median
overall survival time is increased in patients without amplification. A French study showed
response rate to palliative RT according to MYCN status was 47.6% in patients with amplified
MYCN vs. 75.7% in patient without amplification of MYCN (p = 0.04) [6, 9].

5. Investigation
Medical history including family history and physical examination is needed before proceeding for any investigations.
• Laboratory studies: urine examination for catecholamine homovanillic acid (HVA) and
vanillylmandelic acid (VMA)
• Imaging: abdominal ultrasound and computed tomography/MRI (calcification on imaging
is a favorable sign)
• MIBG (metaiodobenzylguanidine) scan, bone scan, and positron emission tomography
(PET) scan
• Biopsies and bilateral bone marrow biopsy

6. Staging
Most commonly used system is the International Neuroblastoma Staging System (INSS)
based on clinical, radiographic, and surgical findings (see Figure 3).
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Figure 3. The International Neuroblastoma Staging System (INSS) [10, 11].

Figure 4. Showing the International Neuroblastoma Staging System (INRGSS) [10, 11].

Later, the International Neuroblastoma Risk Group Staging System (INRGSS) and International Neuroblastoma Risk Group Consensus Pretreatment Classification are released.
INRGSS is using pretreatment tumor imaging rather than extent of surgical resection [10].
The INRGSS is explained in Figure 4.

7. Management
1. For stage I and II disease, the treatment is complete removal of both the primary tumor and
its adjacent involved lymph nodes. Cytoreductive removal of the maximum tumor burden
can be done in more advanced stage with expertise of oncosurgeons.
2. Surgical resection is not recommended in stage 4S disease where the neuroblastoma is
prone to spontaneous regression.
3. Multidisciplinary approach with surgery, chemotherapy, and irradiation is a key for neuroblastoma treatment depending on patient age, disease stage, response to therapy, and tumor
relapse. Local control, metastatic control, and the prevention of relapse are the goal of treatment
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7.1. Radiotherapy
In high-risk neuroblastoma, radiation therapy (RT) can be recommended both to the primary
site and to sites of metastatic disease as part of consolidative therapy. RT also plays an integral
part in the palliation of symptoms from metastatic disease. RT can be used to treat emergencies such as:
• Cord compression
• Tracheal compression
• Expanding retro-orbital tumor
• Imminent bone fracture
• Rapidly enlarging liver
7.1.1. Radiation therapy techniques
7.1.1.1. Three-dimensional conformal radiation therapy
Three-dimensional conformal radiation therapy (3DCRT) is considered the gold standard
practice to treat metastases. Conformal dose distribution to the target volume and dose reduction to the surrounding normal tissues is achieved by 3DCRT. In 3DCRT planning, after making the patient comfortable and in reproducible position, adequate immobilization is done by
immobilization devices. Three-dimensional anatomic information is obtained on CT simulator or MRI. Three-dimensional conformal plans are generated to deliver high doses within
the tumor which is the target and spare the adjacent normal structures at the same time. In
the case of vertebral metastasis, radiation portals should include the involved vertebral body
(and the soft tissue if involved by the tumor), plus a vertebral body below and above. Patients
can be treated in either supine or prone position. If bony metastatic sites are very painful and
there is difficulty in prone position, patient can be made comfortable in supine position, and
this is also an acceptable reproducible position. A three-dimensional plan composed of one
anteroposterior field and two posterior oblique wedged field is illustrated in Figure 5. The
dose prescribed is 20 Gy at 4 Gy per fraction. Hypofractionated radiotherapy is minimally
toxic and time efficient for palliation purpose.
7.1.2. Treatment volumes
Delineation of target volumes is done by CT-based planning. The gross tumor volume of the
primary (GTVp) should include post-induction chemotherapy and presurgical disease. For
abdominal primaries, the clinical target volume (CTVp) included the para-aortic lymph nodes
in addition to the GTVp. Setup uncertainties are reduced by the generation of planning target
volume (PTVp) through expansion of the CTVp approximately 0.5–1.0 cm. For metastatic sites
irradiation, the GTVm consisted of the residual metastatic tumor (following induction chemotherapy) as defined by MIBG, CT, or MRI. An additional 1.0–1.5 cm CTVm margin for microscopic disease followed by a 0.5–1.0 cm PTVm margin will account for setup uncertainties.
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Figure 5. Isodose distribution for three-dimensional conformal radiotherapy (3DCRT) to vertebra.

The 6MV photon energy is delivered by linear accelerator. Wedges and compensators are
used to make the dose distribution more uniform. Whole PTV should be included within
the 95% isodose surface. Not >10% of the PTV should achieve >110% of the prescription dose
(evaluated by DVH) [12].
If dose prescription is 21.6 or 36 Gy, then constraints defined by ANBL0532 AOR are the
contralateral kidney in which V12 should be <20% and V8 < 50% and the liver in which V9
should be <50% and <25% to receive 18 Gy. With these conservative doses, Kandula et al. did
not observed any hepatic or renal toxicity [12].
When treating a child with intensity-modulated radiotherapy (IMRT) techniques, the theoretical increase in secondary malignancies should be considered. For volumes exposed to
low-dose RT, IMRT significantly increased the normal tissue volume receiving 50% or less of
the prescribed dose for the volumes exposed to low-dose RT. The decision to irradiate a metastatic site should be made by the treating physician depending upon the evaluation based on
post-induction response and posttransplant or preradiotherapy imaging.
7.1.3. Radiotherapy doses
Most of the studies recommend that the median RT dose to the primary site is 21.6 Gy (range
21.0–30.6 Gy). Metastatic sites can be irradiated concurrently with the primary site [13]. The
median RT dose recommended to metastatic sites is 21.6 Gy (range 21.0–30.6 Gy) in 12 fractions [12]. Casey et al. reviewed results of RT to metastatic sites as a part of consolidative
therapy at a single institution between 2000 and 2015. Among 159 patients, 229 metastases
were irradiated. Median dose of 21 Gy (10.5–36 Gy) was given to 90% of irradiated metastasis.
Out of 229 irradiated metastasis, 35(15%) had tumor recurrence. These irradiated metastatic
sites had 81.3% 5-year local control. There was no difference in local control as far as number
of metastatic sites is irradiated. Also the site of metastatic bone versus soft tissue irradiation
had no impact on local control, but there was improved overall survival (OS) 59.5% seen in
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cases who were controlled at metastatic site than those patients whose disease was persistent,
and OS in these patients was 18.3% with p = 0.0003 [14].
7.1.3.1. Response rate in palliative radiotherapy
RT is effective in controlling metastatic deposits and in decreasing symptoms due to metastatic disease, with a response rate of 65.2% observed in various studies. Response rates varied
with the type of metastases: 84.2% in soft tissue metastases and 63.2% in bone metastases [9].
7.1.4. Bone metastases
There are many established fears about the long-term impact of RT in children like growth
disturbances or other skeletal abnormalities after irradiation of the musculoskeletal system.
Radiotherapy is performed primarily in these patients with incurable or metastatic disease
to relieve pain, definitely control a bone affected from metastases, and prevent pathologic
fractures as well as spinal cord compression.
7.1.4.1. Radiotherapy doses for bone metastasis
Dose schedule ranges from 6 to 40 Gy [9]. Fraction regimens can be given from 1.8 to 4 Gy
per fraction. The most commonly irradiated sites reported are the lower limb (34%) and spine
(29%). An overall response rate of 65–77% is reported in various studies [9, 15, 16]. The Institut
Curie, Paris, France, published a series of 23 children with neuroblastoma treated for 38 bony
metastatic sites with doses ranging from 6 to 40 Gy. A trend toward improved response with
higher doses was seen (Tables 1 and 2) [9].
7.1.5. Soft tissue metastasis
In soft tissue metastasis, mediastinum, supraclavicular, cervical, axillary, abdominal, and
orbital sites are often involved.
7.1.5.1. Fractionation schedule
The optimal fractionation schedule is still an unresolved issue. Doses can be given as 20 Gy,
with a range from 8 to 36 Gy [9]. Various fraction regimens, including 1.5–4 Gy per fraction,
can be given in palliative setting. Figure 6(a and b) illustrates 3DCRT radiotherapy treatment
of olfactory neuroblastoma with extension into maxillary sinus, ethmoid, orbital, and neck
nodes metastasis.

Total dose

Response

p Value

<20 Gy

50%

0.088

≥20 Gy

81.2%

Table 1. Response to radiotherapy according to dose delivered for bone metastases.

Radiation Therapy in Metastatic Neuroblastoma
http://dx.doi.org/10.5772/intechopen.80892

Myc status

Good response

P value

Myc amplified

26%

0.70

Myc nonamplified

56.5%

Table 2. Response to radiotherapy in 23 patients with bone metastasis according to MYCN status.

Figure 6. (a and b) Isodose distribution for three-dimensional conformal radiotherapy (3DCRT) to the nose, orbit, right
maxilla (Figure 6a), and ipsilateral neck (Figure 6b) with wedge for homogenous dose distribution. Blue represents 95%
of the isodose line.

7.1.6. Radiotherapy for hepatomegaly (stage 4S)
Massive hepatomegaly causes respiratory distress. To prevent respiratory compromise, the
liver is irradiated for symptomatic stage 4S disease. Doses can be given as 450–600 cGy in
2–4 fractions (450 cGy in 3 fractions, 1.5 Gy/fraction) [15]. Target volume can be treated by
opposed lateral fields to avoid renal and ovarian exposure.
7.1.6.1. Radiotherapy borders
Radiotherapy box field should be gridded as anterior border 2 cm anterior to the liver, posterior border should be anterior to vertebral body, superior border 2 cm superior to the liver,
and inferior border gridded at superior iliac crest to avoid ovarian exposure.
Although very rare but one study reported by Paulino showed survival of one patient stage
4S neuroblastoma with liver metastases who was alive 13 years after hepatic irradiation [15].
7.1.7. Intracranial metastasis of neuroblastoma (IMN)
CNS lesions are defined as leptomeningeal disease or metastatic deposits in the CNS parenchyma. Patients with radiographic evidence of bone involvement or with intracranial extension
from the epidural, dura, or skull are not classified with CNS neuroblastoma. Patients who experience a disease recurrence incidence of leptomeningeal or CNS parenchymal disease range
from 1 to 16%. The overall incidence rate for newly diagnosed patients is approximately 6.3%.
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The incidence rate is >10% in cases who are treated with recent intensive chemotherapy and
immunotherapy (N6 and N7, with which the expected cure rate is ≥38%) [17].
Symptoms of CNS involvement are listed in Box 1. Patients with neurologic symptoms
should undergo physical examination and further neuroimaging with head/orbit CT and/or
MRI scans. MIBG scan is not a reliable indicator of CNS disease as false-negative MIBG scans
appear to be common for patients with CNS lesions. This is due to difficulty in discriminating
CNS lesions from skull lesions without SPECT images.

•

Headaches

•

Nausea and emesis

•

Seizures

•

Motor weakness and paralysis

•

Extremity or back pain

•

Change in consciousness

•

Cranial nerve symptoms

•

Fever

Box 1. Clinical features of patients with central nervous system involvement.

7.1.7.1. Genetic associations in brain metastasis
Neuroblastoma tumors that exhibited MYCN amplification correlate with high-risk disease
and poor prognosis as they developed CNS recurrence.
7.1.7.2. External beam radiotherapy in CNS metastasis
Prognosis is very poor even if multimodality treatment is given. Multiple brain metastasis
can be treated by whole brain radiotherapy. In patients with oligometastasis in the brain,
literature suggested that stereotactic radiosurgery (SRS) confers survival benefit [18].
7.1.8. Gamma knife radiosurgery
Nathan C. Rowland et al. described in literature two cases of the application of SRS to high-risk,
recurrent IMN. Leksell Gamma Knife model 4C using Leksell GammaPlan 4C treatment planning software was used for radiotherapy. First patient 5-year-old male was treated case of neuroblastoma whose brain magnetic resonance imaging (MRI) showed a 4.0 × 3.3 cm mass in the
right parietal lobe with a small amount of surrounding edema and midline shift. The dose prescription was 27.7 Gy to 47% isodose line. The 18 mm and 14 mm collimating helmets were used
in 18 targets. Target volume was 29.2 cc and 100% target coverage was by prescribed isodose
line. Conformity index of 1.34 was achieved. Radiological follow-up at 2 and 4 months revealed
stable reduction of disease. Patient again received chemotherapy and 21.6 Gy dose given to
craniospinal axis. Three-month post-radiotherapy intra-ommaya therapy along with complete
surgical excision of mass was given. CNS relapse occurred 15 months after radiotherapy and
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patient gave up to disease. The second case was 2 ½-year-old male treated case of neuroblastoma which showed solid mass in the left parieto-occipital lobe measuring 1.8 × 1.0 cm with a
small anterior cystic component. Stereotactic biopsy of the intracranial mass diagnosed the neuroblastoma. A dose of 14 Gy was prescribed to the 50% isodose line and this was administered
to five targets. The 18 mm collimating helmet was utilized. Although radiological follow-up at 2
and 3 months showed reduction in size of initial parieto-occipital lesion, 4-month follow-up CT
scan showed slight progression in size of metastatic lesion with vasogenic edema. Finally after
CNS relapse which occurred 7 ½-month post-radiotherapy, patient died of disease. Stereotactic
radiosurgery is an acceptable palliative method in the treatment of IMN [19].
7.1.9. Proton beam therapy
Proton beam therapy (PBT) is a good alternative to photon therapy for pediatric patients
where post-radiotherapy side effects are concerned. PBT delivers radiation within a defined
radiation track length, with virtually no dose beyond the intended target due to Bragg peak
(Figures 7 and 8). Proton beam provides superior target volume coverage and greater dose
reductions for normal tissues or organs at risk by a factor of 1.5–3.0 than photon beam. This
is due to additional benefit of no exit dose and low entrance dose [20]. Proton beam is considered safe for neuroblastoma pediatric patients with minimal risk of secondary cancer which
is slightly higher with intensity-modulated radiotherapy (IMRT) due to peripheral doses. As
discussed earlier, doses in path of proton beam are very minimal. There is homogenous dose
distribution with large volume of neuroblastoma with less number of ports than IMRT [21].
7.1.10. Procedure
Before treatment, CT images for PBT planning are to be obtained at intervals of 2–5 mm in the
treatment position. The interval depends on the age, height, and treatment site of the patient.
The gross tumor volume (GTV) is defined as the tumor volume before PBT for a recurrent
tumor. The clinical target volume (CTV) is defined as the GTV plus a 1.5 cm margin, and the
PTV is defined as the CTV plus a 0.5–0.7 cm margin. Toxicity and treatment effect should be

Figure 7. Bragg peak of proton is very sharp.
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Figure 8. Sharp reduction of dose to brain tissue by proton irradiation.

balanced in determining the CTV. Sedatives can be administered for planning CT and treatment in pediatric patients.
The photon equivalent dose (GyE) = [Physical Dose (Gy)] × [Relative Biological Effectiveness
of the proton beam]. This is assigned with a value of 1.1.
The PBT doses usually administered from 19.8 to 45.5 GyE (median: 30.6 GyE) [21].

8. Summary
• Radiotherapy can be considered to primary site or residual MIBG-positive metastatic site.
• Palliative radiotherapy is given on individual case to case basis.
• Abdominal and pelvic sites are commonly treated with AP fields or 3DCRT techniques.
Plans should be with the use of multileaf collimators (MLC).
• Dose: 21.6 Gy in 12 fractions (1.8 Gy per fraction).
• GTV (primary tumor volume) = pre-surgery CT/MIGB scans.
• Bone metastatic site = volume positive on MIGB/bone scan after induction chemo.
• PTV = GTV + 2 cm.
Dose constraints for liver normal parenchyma are V9 Gy <50% and V18 Gy <25%; contralateral kidney constraints are V8 Gy <50% and V12 Gy <20%.
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